All In Biotech

Drug Trial Radar · NCT01661101

Management of Myocardial Injury After Noncardiac Surgery Trial

A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery

Last checked: Nov 20, 2026Latest source record: Mar 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,754 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,754

Actual

Start

Jan 2013

Primary completion

Mar 1, 2018

Study completion Mar 1, 2018

Sponsor

Lead sponsor
Population Health Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 9, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients who have myocardial injury after noncardiac surgery are at a higher risk of dying than those who do not. One in 10 patients with myocardial injury will die within 30 days of surgery. This risk of death exists up to one year after myocardial injury. There are currently no treatments or guidelines available for heart injury after surgery, but there is evidence that taking a blood-thinner can prevent some of the deaths, both in the short and long-term. The purpose of this trial is to test the effect of two drugs (dabigatran and omeprazole) that may prevent mortality, major cardiovascular complications and major upper gastrointestinal bleeding in patients who have had myocardial injury after noncardiac surgery.

Conditions

  • Myocardial Injury After Noncardiac Surgery (MINS)

Interventions

  • DabigatranDrug

    Dabigatran 110 mg taken twice daily

  • Placebo (for Dabigatran)Drug

    Dabigatran placebo taken twice daily

  • OmeprazoleDrug

    Omeprazole 20 mg capsule taken once daily

  • Placebo (for Omeprazole)Drug

    Omeprazole placebo taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major vascular complication (for Dabigatran)Time frame: Average of 1 year follow-up
  2. Major upper gastrointestinal complication (for Omeprazole)Time frame: Average of 1 year follow-up

Locations

82 sites in 19 countries. Site status is shown where the registry gives one.

  • Kansas University Medical Center

    Kansas City, Kansas

  • VA Western New York Healthcare System

    Buffalo, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Wake Forest School of Medicine

    Winston-Salem, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Drexel University College of Medicine

    Philadelphia, Pennsylvania

  • VA North Texas Health Care System Dallas VA Medical Center

    Dallas, Texas

  • Favaloro Foundation

    Buenos Aires, Argentina

  • Hospital San Roque

    Córdoba, Argentina

  • Instituto Cardiovascular de Buenos Aires

    Caba, Buenos Aires, Argentina

  • Clinica Parra - Centro de Investigaciones

    Rafaela, Santa Fe Province, Argentina

  • Sanatorio San Martin

    Venado Tuerto, Santa Fe Province, Argentina

  • Westmead Hospital

    Westmead, Australia

  • Hospital Lifecenter

    Belo Horizonte, Brazil

  • Hospital e Maternidade Celso Pierro - PUCCAMP

    Campinas, Brazil

  • Hospital Barra D'Or

    Rio de Janeiro, Brazil

  • Hospital de Base

    São José do Rio Preto, Brazil

  • Hospital Maternidade

    Poços de Caldas, Minas Gerais, Brazil

  • Sociendade Hospitalar Angelina Caron

    Campina Grande do Sul, Paraná, Brazil

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Grey Nuns Hospital

    Edmonton, Alberta, Canada

  • Health Sciences Centre Winnipeg

    Winnipeg, Manitoba, Canada

  • Hamilton General Hospital

    Hamilton, Ontario, Canada

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, Canada

  • Juravinski Hospital and Cancer Centre

    Hamilton, Ontario, Canada

  • Queens University - Kingston General Hospital

    Kingston, Ontario, Canada

  • University Hospital, London Health Sciences Centre

    London, Ontario, Canada

  • Victoria Hospital, London Health Sciences Centre

    London, Ontario, Canada

  • Centre Hospitalier Universitaire de Montreal - St. Luc Hospital

    Montreal, Quebec, Canada

  • Montreal General Hospital - McGill University Health Centre

    Montreal, Quebec, Canada

  • Fundacion Cardioinfantil - Instituto de Cardiologia

    Bogotá, Colombia

  • Clinica Foscal

    Floridablanca, Santander Department, Colombia

  • Liberec Regional Hospital

    Liberec, Czechia

  • University Hospital Motol

    Motol, Czechia

  • Bispebjerg Hospital, University of Copenhagen

    Copenhagen, Denmark

  • Copenhagen University Hospital, Rigshospitalet

    Copenhagen, Denmark

  • Herlev Hospital

    Herlev, Denmark

  • Nordsjaellands Hospital

    Hillerød, Denmark

  • Koege-Roskilde Hospital

    Køge, Denmark

  • Vejle Hospital

    Vejle, Denmark

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.